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64566 | RSC Adv., 2015, 5, 64566–645and evaluation of new
biomolecule-based coumarin–thiazoline hybrids as
potent anti-tubercular agents with cytotoxicity,
DNA cleavage and X-ray studies†‡
Dinesh S. Reddy,a Kallappa M. Hosamani,*a Hirihalli C. Devarajegowdab
and Mahantesh M. Kurjogic
An eﬃcient and rapid synthesis of coumarin–thiazoline hybrids (1a–1j) under microwave irradiation is
described with high yields. The synthesized compounds were characterized using elemental and
spectroscopic analysis; in addition, the structures of compounds 1a, 1b, 1e and 1h have been elucidated
using single crystal X-ray diﬀraction techniques. All the newly synthesized compounds were screened for
their in vitro anti-tubercular activity and in a DNA cleavage study, while the most active compounds
were subjected to a cytotoxicity assay on Vero cell lines. Among those tested, compound 1b exhibited
excellent anti-tubercular activity (MIC 0.09 mg ml1) with a low level of cytotoxicity, suggesting that
compound 1b is a promising lead for subsequent investigations in search of new anti-tubercular agents.
Furthermore, a DNA cleavage study using an agarose gel electrophoresis method revealed that
compounds 1b, 1d, 1f and 1i cleaved DNA more eﬃciently and thereby exhibit nuclease activity.Introduction
Today, classic drug development works with small, chemically
manufactured active substance molecules, since these mole-
cules can reach almost any desired destination in the body and
their small structure and chemical composition oen helps
them to easily penetrate cell membranes and thereby increases
the bioavailability of the compound.1 Hence the majority of
pharmaceuticals and biologically active drugs are all small-
sized molecules. Based on these facts, medicinal chemist
Christopher Lipinski and his colleagues, in the year 1997,
analyzed the physicochemical properties of more than 2000
drugs and candidate drugs in clinical trials, and concluded that
a compound is more likely to be membrane permeable and
easily absorbed by the body if it matches the Rule of Five (RO5).2
The rules, based on the 90 percentile values of the analysed, Karnatak University, Dharwad-580003,
ax: +91-836-2771275, +91-836-2747884;
, University of Mysore, Mysore-570005,
y & Biotechnology, Karnatak University,
beloved Prof. M. V. Kulkarni on his 60th
(ESI) available. CCDC 897299, 897300,
ystallographic data in CIF or other
508e
81drugs’ property distributions, apply only to absorption by
passive diﬀusion of the compound through cell membranes;
compounds that are actively transported through cell
membranes by transporter proteins are exceptions to the rule.
Furthermore, candidate drugs that conform to the RO5 tend to
have lower attrition rates during clinical trials and hence have
an increased chance of reaching the market.3 Hence, keeping
these factors in view the architecture of the compounds was
designed and their physicochemical properties (RO5) were
analyzed which are listed below.
 All the newly synthesized compounds’ molecular weights
fall below the 500 daltons limit.
 The compound’s lipophilicity, expressed as a quantity
known as log P, is less than 5 (log P values of all the compounds
were calculated using http://www.molinspiration.com) and the
values are given in Table 2.
 The number of groups in the molecule that can donate
hydrogen atoms to hydrogen bonds is less than 5 (expressed as
the sum of OHs and NHs).
 The number of groups that can accept hydrogen atoms to
form hydrogen bonds is less than 10 (estimated by the sum of
Os and Ns).
From the results, it is clear that none of the compounds
violate the rules and they fall well within the range as stated by
the RO5 to qualify as a drug candidate.
Coumarins are an elite class of oxygen-containing fused
heterocycles, which are widely distributed in nature, especially
in plants. They form a large class of important lactones with aThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinefused structure of benzene and an a-pyrone ring, and virtually
contain a p–p conjugated system rich in electrons and with
good charge transport properties. Moreover, the unique struc-
ture of coumarin has a special ability which allows its deriva-
tives to readily interact with a diversity of enzymes and receptors
in organisms through weak bond interactions and thereby
exhibit wide potential as medicinal drugs. Hence, coumarin
based compounds have attracted special interest in the area of
medicinal chemistry and their outstanding contributions in the
prevention and treatment of numerous diseases have become
an extremely attractive highlight.4 Recently many coumarin
scaﬀolds have been investigated as potential candidates for the
treatment of tuberculosis, e.g. diaryl coumarin (1, Fig. 1), 4-aryl/
alkyl sulfonyl methyl coumarin (2), iodinated-4-aryloxymethyl
coumarin (3) and chalconated coumarin (4) have been repor-
ted to exhibit potent anti-tubercular activity with MICs of 0.24,
0.78, 1.56 and 3.5 mg ml1 respectively,5 whereas naturally
occurring coumarins such as ferulenol (5), suberosin (6), osthol
(7), scopoletin (8) and umbelliferone (9) have exhibited MICs of
2, 16, 32, 42 and 58.3 mg ml1 respectively.6 Reports have also
suggested that the coumarin class of compounds targets the
fatty acyl-ACP synthetase activity of the FadD32 enzyme5a,6a
which is essential forMtb survival as it plays a critical role in the
biosynthesis of the unique branched fatty acids (mycolic acids)
that make up the Mtb cell wall. Hence looking into the biolog-
ical signicance of coumarins, particularly in the eld of
tuberculosis, we anticipate that coumarins could be a good
starting point for the development of new lead anti-tubercularFig. 1 Synthetic and natural occurring coumarin derivatives exhibiting a
This journal is © The Royal Society of Chemistry 2015drugs. Fig. 1 represents the structures of some potent
coumarin scaﬀolds exhibiting anti-tubercular properties.
Thiazoline (partially reduced thiazole) is a heterocyclic
compound containing both sulfur and nitrogen in the ring. It is
a structural segment of various cyclopeptide alkaloids extracted
from diﬀerent marine organisms.7 Lissoclinamide (1, Fig. 2),
patellins (2), tawicyclamides (3), bistratamides (4), and trunka-
mides (5) were extracted from Lissoclinum patella, whereas
dolastatin E (6) and apratoxins (7) were isolated from Dolabella
auricularia and Lyngbya majuscula8 respectively. Reports have
shown that lissoclinamide (1) having two thiazoline rings was
found to be the most cytotoxic when tested with human bro-
blasts, bladder carcinoma cell lines, and normal lymphocytes
(IC50 < 0.1 mg ml
1),9 whereas trunkamide (5) was reported to
have promising antitumor activity10 (Fig. 2).
Recently, many research groups have paid attention to the
chemical properties of thiazolines, mainly due to the unique
properties of the sulfur and nitrogen. The derivatives are oen
bioactive, exhibiting interesting biological activities like anti-
microbial, anti-inammatory, anticancer and anti-HIV activity,
pheromone activity and cell division inhibition,11–16 while small
molecular mass thiazolines have found applications in the food
and avor industries.17 However, it’s surprising that thiazolines
have not been much explored in the eld of tubercular activity
though they have been found to be good antibiotics.18 Hence,
looking into the biological signicance of thiazoline particu-
larly in the eld of antibiotics, it was desirable for us to intro-
duce thiazoline into the sub-substructure of the compounds by
conjugating diﬀerent coumarin derivatives with thiazoline;nti-tubercular properties.
RSC Adv., 2015, 5, 64566–64581 | 64567
Fig. 2 Cyclopeptide alkaloids containing thiazoline as a structural segment.
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View Article Onlinesince the conjugation of coumarin derivatives with various
bioactive molecules such as resveratrol, tacrine, thiazol-
pyrazole, triazole, chalcone and pyrimidine has produced
novel hybrid molecules, which are endowed with vasorelaxant,
platelet anti-aggregating, Alzheimer’s disease treatment, anti-
microbial, antioxidant, Hsp90 C-terminal inhibitor, antioxi-
dant, trypanocidal and anti-cancer properties.19 Furthermore,
hybridized compounds have diverse or dual modes of action,
multiple biological activities, modied selectivity proles and
reduced undesired side eﬀects. Such molecules may be further
modied to exhibit favorable pharmacokinetics and oral
bioavailability.20
Thioether linkages are present in many bioactive natural and
pharmaceutical products. However it’s surprising that in
comparison to the amount of eﬀort devoted to the discovery of
new methods for preparing C–C, C–O, and C–N bonds,
considerably less resources have been allocated to the devel-
opment of preparing C–S bonds.21 In fact, it has been demon-
strated in several instances that replacing a carbon or oxygen
atom with sulfur greatly enhances the bioactivity of certain
compounds with respect to their oxygenated or carbon coun-
terparts.22 For example, SAR studies have shown that for diallyl
sulde, which exhibits potent anticancer properties,22 a single64568 | RSC Adv., 2015, 5, 64566–64581sulfur atom bonded to at least one allyl side chain is required
for inhibition of carcinogenesis.23 A number of drugs, which are
applied for the treatment of Alzheimer’s disease, Parkinson’s
disease, and diabetes, as well as immune and inammatory
diseases, carry aryl sulde moieties on their backbone unit.24
Furthermore, the thioether linkage has provided compounds
with diverse antagonistic properties against the histamine H2-
receptor, e.g. cimetidine25 (Tagamet) (1), famotidine26 (Pepcid)
(2), and ranitidine27 (Zantac) (3) are being used to treat and
prevent ulcers; the thioether linkage in an immunity-related
conjugate between doxorubicin and the monoclonal antibody
BR96 was demonstrated to be critical to its antitumor proper-
ties28 (4); and meropenem29 (5) has been used as an antibiotic
drug (Fig. 3). Hence, it is apparent that the development of
novel thioethers, and more generally, C–S bonds, would be of
great benet to both chemists and biologists for developing
potent drugs.
Hence, motivated by the inherent biological relevance of
coumarin, thiazoline, and thioether, the present investigation
pertains to the hybridization of two active pharmacophores
(coumarin & thiazoline) via a thioether linkage. It is expected
that the additive eﬀect of this combination might produce a
synergetic eﬀect in enhancing the bio-activity of the compound.This journal is © The Royal Society of Chemistry 2015
Fig. 3 Bioactive thioether linked compounds.
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View Article OnlineThe designed hypothetical interaction model is represented in
(Fig. 4). To further our continued eﬀort towards the develop-
ment of microwave assisted synthetic methodologies,19f,30 we
describe in this paper an eﬃcient and facile synthesis of
coumarin–thiazoline hybrids (1a–1j) under microwave irradia-
tion, through which the yields of the compounds were improved
drastically in a very short reaction time as compared to
conventional methods.Results and discussion
Chemistry
The substituted 4-bromomethyl coumarins (a–j) were synthe-
sized using a Pechman cyclisation of the phenols with 4-bro-
moethylacetoacetate.31 Condensation of the 4-bromomethyl
coumarin (a–j) (0.01 mol) with 4,5-dihydrothiazole-2-thiol (1)
(0.01 mol) in anhydrous K2CO3 (0.03 mol) using absolute
ethanol as the solvent aﬀorded 4-[(4,5-dihydro-1,3-thiazol-2-
ylthio)methyl]substituted-2H-chromen-2-one derivatives (1a–1j)Fig. 4 Design strategy to enhance anti-tubercular activity (hypo-
thetical interaction model).
This journal is © The Royal Society of Chemistry 2015under both conventional and microwave irradiation methods.
Synthesis of the target compounds was carried out as outlined
in Scheme 1. From the results, it is clear that the microwave
approach proved to be extremely fast, providing good to excel-
lent yields (81–91%) as compared to the conventional method
(61–75%). Here the most noticeable advancement was the speed
with which the reactions were completed i.e. within 5–9
minutes, which is 90–120 times faster than the conventional
method. The results are summarized in Table 1.
All the newly synthesized compounds were characterized
using FTIR, 1H NMR, 13C NMR, mass and elemental analysis.
The spectral data of the newly synthesized compounds (1a–1j)
are provided in the experimental section, and are in accordance
with the assigned structures of the compounds. The 1H and 13C
NMR spectra of all the compounds are given in the ESI‡ and are
in good agreement with the proposed structure of the
compounds. In the case of compound 1a (R ¼ 6CH3), the IR
spectrum exhibited two characteristic bands at 1713 cm1 for
the lactone of the coumarin and 1574 cm1 for the imine of the
thiazoline moiety. The formation of the product was established
using the 1H NMR spectrum, wherein a sharp singlet at d 4.45
ppm corresponds to the –CH2–S, conrming the formation of
the condensed product via thioether linkage, and the presence
of two triplets at d 3.45 ppm and d 4.23 ppm corresponds to the
]N–CH2 and –S–CH2 of the thiazoline ring respectively. Two
singlets were observed in the aromatic region at d 6.56 and d
7.40 ppm, corresponding to the C3–H and C5–H of the coumarin
moiety respectively, whereas the C7–H and C8–H of the
coumarin resonate as doublets at d 7.24 and d 7.34 ppm
respectively, while themethyl protons were observed as a singlet
at d 2.42 ppm which corresponds to the C6–CH3 of the
coumarin. The 13C NMR spectrum provides additional supportRSC Adv., 2015, 5, 64566–64581 | 64569
Scheme 1 Synthetic route to synthesize the title compounds (1a–1j).
Table 1 Comparison between the conventional and microwave irra-
diation methods
Product R
Yield (%) Time (min)
Ca Mb C M
1a 6-CH3 63 88 600 5
1b 6-Cl 71 83 630 7
1c 6-OCH3 75 91 670 6
1d 5,6-Benzo 64 82 810 8
1e 7-CH3 66 86 640 6
1f 7-Cl 68 84 650 7
1g 7-OCH3 69 87 720 6
1h 5,7-diCH3 61 81 840 9
1i 6-Br 64 88 730 8
1j 7-Br 62 87 720 8
a C – conventional. b M – microwave.
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View Article Onlinefor the structure of the compound (1a), wherein the lactone
carbonyl resonated at d 160.73 ppm, the thioether linked –S–
CH2 resonated at d 36.10 ppm, and the –C]N of the imine
resonated at d 163.59 ppm, whereas the –S–CH2 and ]N–CH2
corresponding to the thiazoline ring resonated at d 32.06 ppm
and d 63.89 ppm respectively, and the methyl carbon resonated
at d 21.03 ppm which corresponds to the C6–CH3 of the
coumarin. The molecular ion peak at 291[M]+ in the GC-MS
spectrum conrmed the proposed structure for compound 1a.
The rest of the compounds gave satisfactory analytical and
spectroscopic data which were in accordance with their
assigned structures.
X-ray diﬀraction analysis
Single crystals for compounds 1a, 1b, 1e and 1h were developed
by slow evaporation of chloroform at room temperature.
Compounds 1a, 1b and 1e crystallized under a triclinic system
with the space group P1 and compound 1h under a monoclinic
system with the space group P21/c. The unit cell dimensions for64570 | RSC Adv., 2015, 5, 64566–64581compound 1a are as follows: a ¼ 7.93370(10) A˚, b ¼ 8.09230(10)
A˚, c ¼ 10.7299(2) A˚, a ¼ 99.1900(10), b ¼ 92.5250(10), g ¼
96.4970(10), Z ¼ 2. For compound 1b the unit cell dimensions
are: a ¼ 7.3443(3) A˚, b ¼ 7.7814(3) A˚, c ¼ 12.6804(4) A˚, a ¼
85.486(2), b ¼ 82.226(2), g ¼ 65.984(2), Z ¼ 2. For compound
1e the unit cell dimensions are: a¼ 7.8774(2) A˚, b¼ 8.4986(3) A˚,
c ¼ 11.2330(3) A˚, a ¼ 91.435(2), b ¼ 107.376(2), g ¼
107.927(2), Z ¼ 2; whereas for compound 1h the unit cell
dimensions were found to be: a ¼ 7.2356(8) A˚, b ¼ 7.9426(10) A˚,
c ¼ 25.027(3) A˚, a ¼ 90, b ¼ 96.742(8), g ¼ 90, Z ¼ 4. The
structures were solved and rened using SHELXS-97.‡32
X-ray analysis for compound 1a. From the crystal data it was
observed that the asymmetric unit of compound 4-[(4,5-dihy-
dro-1,3-thiazol-2-ylthio)methyl]-6-methyl-2H-chromen-2-one
(1a) contains only one independent molecule. The crystal
structure shows weak intramolecular C16/H16B/N5 & C7/
H7/S2 hydrogen bonds and is further stabilized by intermo-
lecular C15–H15C/S2 hydrogen bonds, that generate inversion
dimers with R22(16) ring motifs. The 2H-chromene ring systems
is nearly planar, with a maximum deviation of 0.0234(17) A˚ for
atom C9. In the crystal structure, the bond length C17–S1 ¼
1.7705(2) A˚ is longer than the bond length of C18–C19 ¼
1.498(3) A˚ and the bond angle C17–S1–C19 ¼ 88.60(10) is less
than the bond angle of C17–N5–C18 ¼ 110.45(9). As a result of
these diﬀerences in the molecular parameters, the thiazoline
ring adopts a nearly twisted form conformation. The dihedral
angle between the 2H-chromene ring (O3/C6–C14) and the
thiazoline ring (N5/S1/C17–C19) is 82.72(10). The packing of
the crystal structure is stabilized by C19–H19A/p Cg(3) (C9–
C14) interactions as well as p–p [Cg(2) (O3/C6–C10)/Cg(3) (C9–
C14)] interactions between the fused benzene and the pyrone
ring of the coumarin moieties [shortest centroid–centroid
distance ¼ 3.6368 (10) A˚]. The packing of the molecules
exhibited layered stacking when viewed down the a-axis. These
layers are linked via hydrogen bonds, which in turn form a
linear polymeric chain. The X-ray structure parameters and
renement for compound (1a) are presented in Table 2. TheThis journal is © The Royal Society of Chemistry 2015
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View Article OnlineORTEP and packing diagrams of compound 1a are portrayed in
Fig. 5.
X-ray analysis for compound 1b. From the crystal data it is
known that the asymmetric unit of 6-chloro-4-[(4,5-dihydro-1,3-
thiazol-2-ylthio)methyl]-2H-chromen-2-one (1b) contains only
one independent molecule. The crystal structure shows weak
intramolecular C8/H8/S3 and C16/ H16B/N6 and inter-
molecular C16/H16A/O5 hydrogen bonds and is further
stabilized by intermolecular C16–H16B/Cl1 hydrogen bonds,
that generate inversion dimers with R22(14) ring motifs. The 2H-
chromene ring (O4/C7–C15) system is nearly planar, with a
maximum deviation of 0.0202(23) A˚ for atom C13. In the crystal
structure, the bond length C17–S2 ¼ 1.7595(2) A˚ is longer than
the bond length of C18–C19 ¼ 1.495(4) A˚ and the bond angle
C17–S2–C19 ¼ 89.31(12) is less than the bond angle of C17–
N6–C18 ¼ 111.0(2). As a result of these diﬀerences in the
molecular parameters, the thiazoline ring adopts a nearly
twisted form conformation. The dihedral angle between the 2H-
chromene ring (O4/C7–C15) and the thiazoline (S2/N6/C17–
C19) ring is 89.16(11). The packing of the crystal structure isTable 2 Crystal data, data collection details and structure reﬁnement fo
Empirical formula
Formula weight
Crystal system, space group
Unit cell dimensions
Volume
Z
Calculated density
Crystal size
Absorption coeﬃcient
F(000)
Crystal form
Radiation source
Radiation type
Radiation monochromator
Criterion for observed reection
Data collection
Diﬀractometer
Data collection method
Absorption correction
Theta range for data collection
Limiting indices
Reections collected/unique
Completeness to theta
Max. and min. transmission
Renement
Renement method
Data/restraints/parameters
Goodness-of-t on F2
Final R indices [I > 2s(I)]
R indices (all data)
Weighting scheme
(D/s)max
Largest diﬀ. peak and hole
This journal is © The Royal Society of Chemistry 2015stabilized by p–p [Cg(2) (O4/C7–C11)/Cg(3) (C10–C15)] inter-
actions between the fused benzene and the pyrone ring of the
coumarin moieties [shortest centroid–centroid distance ¼
3.7101 (13) A˚]. The crystal structure parameters for compound
1b are presented in Table 3. The ORTEP and packing diagrams
of compound 1b are portrayed in Fig. 6.
X-ray analysis for compound 1e. From the crystal data it is
known that the asymmetric unit of 4-((4,5-dihydrothiazol-2-
ylthio)methyl)-7-methyl-H-chromen-2-one (1e) contains only
one independent molecule. The crystal structure shows weak
intramolecular C16/H16B/N5 and C7/H7/S2 hydrogen
bonds. In addition, intermolecular C6/H6C/N5 hydrogen
bonds link the components into chains along [100] and
generate inversion dimers with R22(22) ring motifs. The 2H-
chromene ring (O3/C7–C15) system is nearly planar, with a
maximum deviation of 0.0271(18) A˚ for atom C14. In the crystal
structure, the bond length C18–S2 ¼ 1.802(2) A˚ is longer than
the bond length of C18–C19 ¼ 1.522(3) A˚ and the bond angle
C17–S2–C18 ¼ 88.63(9) is less than the bond angle of C17–N5–
C19 ¼ 111.16(15). As a result of these diﬀerences in ther 1a
C14H13NO2S2
291.37
Triclinic, P1
a ¼ 7.93370(10) A˚
b ¼ 8.09230(10) A˚
c ¼ 10.7299(2) A˚
a ¼ 99.1900(10), b ¼ 92.5250(10), g ¼ 96.4970(10)
674.313(2) A˚3
2
1.435 mg m3
0.22  0.15  0.12 mm
0.391 mm1
304
Plate, colourless
Fine-focus sealed tube
Mo Ka
Graphite
I > 2s(I)
Bruker SMART CCD area-detector
u–c scans
Multi-scan
1.93 to 24.99
9 # h # 9, 9 # k # 9, 12 # l # 12
10 734/2376 [R(int) ¼ 0.0200]
99.6%
Tmax ¼ 1.000, Tmin ¼ 0.790
Full-matrix least-squares on F2
2376/0/172
1.059
R1 ¼ 0.0379, wR2 ¼ 0.1108
R1 ¼ 0.0414, wR2 ¼ 0.1141
u ¼ 1/[s2(Fo2) + (0.068P)2 + 0.230P] where P ¼ (Fo2 + 2Fc2)/3
<0.001
0.356 and 0.237e Ǻ3
RSC Adv., 2015, 5, 64566–64581 | 64571
Fig. 5 ORTEP and packing diagrams for compound 1a. Displacement ellipsoids are drawn at the 50% probability level. Hydrogen atoms are
shown as spheres of arbitrary radius.
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View Article Onlinemolecular parameters, the thiazoline ring adopts a nearly
twisted form conformation. The dihedral angle between the 2H-
chromene ring (O3/C7–C15) and the thiazoline ring (S2/N5/
C17–C19) is 63.61(8). The crystal structure also features C/Table 3 Crystal data, data collection details and structure reﬁnement fo
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system, space group
Unit cell dimensions
Volume
Z
Calculated density
Crystal size
Absorption coeﬃcient
F(000)
Crystal form
Radiation source
Radiation type
Radiation monochromator
Criterion for observed reection
Data collection
Diﬀractometer
Data collection method
Absorption correction
Theta range for data collection
Limiting indices
Reections collected/unique
Completeness to theta
Max. and min. transmission
Renement
Renement method
Data/restraints/parameters
Goodness-of-t on F2
Final R indices [I > 2s(I)]
R indices (all data)
Weighting scheme
(D/s)max
Largest diﬀ. peak and hole
64572 | RSC Adv., 2015, 5, 64566–64581H/p [Cg(2); (O3/C10/C11/C13–C15)] and p–p [Cg(2) (O3/C10/
C11/C13–C15)/Cg(3) (C7–C12)] interactions between the fused
benzene and the pyrone ring of the coumarin moieties [shortest
centroid–centroid distance ¼ 3.7698(9) A˚] and shows stackingr 1b
C13H10ClNO2S2
311.79
296 K
0.71073 A˚
Triclinic, P1
a ¼ 7.3443(3) A˚
b ¼ 7.7814(3) A˚
c ¼ 12.6804(4) A˚
a ¼ 85.486(2), b ¼ 82.226(2), g ¼ 65.984(2)
655.63(4) A˚3
2
1.579 mg m3
0.22  0.15  0.12 mm
0.61 mm1
320
Plate, yellow
Fine-focus sealed tube
Mo Ka
Graphite
I > 2s(I)
Bruker SMART CCD area-detector
u–c scans
Multi-scan
1.62 to 24.99
8 # h # 8, 9 # k # 9, 15 # l # 15
9894/2307 [R(int) ¼ 0.0252]
99.8%
Tmax ¼ 1.000, Tmin ¼ 0.790
Full-matrix least-squares on F2
2307/0/172
1.075
R1 ¼ 0.0340, wR2 ¼ 0.0921
R1 ¼ 0.0380, wR2 ¼ 0.0946
u ¼ 1/[s2(Fo2) + (0.0505P)2 + 0.2154P] where P ¼ (Fo2 + 2Fc2)/3
<0.001
0.338 and 0.319e Ǻ3
This journal is © The Royal Society of Chemistry 2015
Fig. 6 ORTEP and packing diagrams for compound 1b. Displacement ellipsoids are drawn at the 50% probability level. Hydrogen atoms are
shown as spheres of arbitrary radius.
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View Article Onlinewhen viewed along the b-axis. The crystal structure parameters
for compound 1e are presented in Table 4. The ORTEP and
packing diagrams of compound 1e are portrayed in Fig. 7.
X-ray analysis for compound 1h. From the crystal data it is
known that the asymmetric unit for compound 4-((4,5-dihy-
drothiazol-2-ylthio)methyl)-5,7-dimethyl-2H-chromen-2-one
(1h) is characterized by a long range, well dened three
dimensional order. The asymmetric unit contains only one
independent molecule as depicted in Fig. 8. The 2H-chromene
ring (O3/C11/C12/C14–C16) system is nearly planar, with a
maximum deviation of 0.0162(13) A˚ for atom C13, and in the
crystal structure, the bond length C20–S2 ¼ 1.802(6) A˚ is longer
than the bond length of C19–C20 ¼ 1.509(8) A˚ and the bond
angle C18–S2–C20¼ 88.0(3) is less than the bond angle of C18–
N5–C19 ¼ 109.6(5). As a result of these diﬀerences in the
molecular parameters, the thiazoline ring adopts a nearly
twisted form conformation. The dihedral angle between the 2H-
chromene ring and the thiazoline ring (S2/N5/C18–C20) is
8.1(3). The crystal structure contains weak intramolecular
C15/H15/S1 hydrogen bonds. In addition, intermolecular
C13/H13/O4 hydrogen bonds link the components into
chains along [010] and generate inversion dimers with R22(12)
ring motifs. The crystal structure also features C7/H7B/p
[Cg(3); (C8–C13)] and p–p [Cg(2) (O3/C11/C12/C14–C16)/Cg(3)
(C8–C13)] interactions between the fused benzene and the
pyrone ring of the coumarin moieties [shortest centroid–
centroid distance ¼ 3.568(3) A˚] and shows stacking when
viewed along the c-axis. The crystal structure parameters for
compound 1h are presented in Table 5. The ORTEP and packing
diagrams of compound 1h are portrayed in Fig. 8.Bioevaluation
The synthesized compounds were screened for their potential in
vitro anti-tubercular activity using a Microplate Alamar Blue
Assay (MABA)33 and in a CT-DNA cleavage study using a gel
electrophoresis method.34 Furthermore, the most active
compounds were tested for their cytotoxicity against Vero cells
using a MTT35 assay.This journal is © The Royal Society of Chemistry 2015Anti-tubercular activity. All the compounds (1a–1j) were
initially screened at a single concentration of 6.25 mg ml1
againstMtbH37Rv (ATCC-27294) in BACTEC 12 Bmedium, using
a Microplate Alamar Blue Assay (MABA). The results are
summarized in Table 6. Compounds exhibiting $90% inhibi-
tion in the initial screening were tested at and below 6.25 mg
ml1 using 2-fold dilution to determine the actual MIC. The
results of the anti-tubercular studies are presented in Table 6. In
the primary screening, most of the compounds displayed 91–
98% inhibition. In the secondary level of screening, four
compounds (1b, 1f, 1i and 1j) inhibited Mtb with a MIC < 1 mg
ml1 and two compounds (1a and 1c) had a MIC < 4 mg ml1,
compared to isoniazid (MIC: 0.02 mg ml1). From Table 6, it is
clear that the halogen (–Cl and –Br) substituted compounds (1b,
1f, 1i and 1j) have shown more signicant anti-tubercular
activity, with MICs in the range 0.09–0.78 mg ml1. Among
them, compounds 1b and 1i exhibited the most pronounced
anti-tubercular activity with a MIC of 0.09 and 0.19 mg ml1
respectively. In particular, compound 1b was found to be the
most active in vitro with a MIC of 0.09 mg ml1. Whereas
compounds 1a and 1c exhibited comparatively good activity
with a MIC 1.56 and 3.12 mg ml1 respectively, while
compounds 1e and 1g showed moderate inhibition againstMtb
with similar MIC values of 6.25 mg ml1. The remaining
compounds 1d and 1h were found to be ineﬀective against the
MtbH37Rv strain. Although from Table 6, no clear relation was
observed between the MIC and the lipophilicity (calculated
log P).
Having identied a good number of active antimycobacterial
compounds (1a, 1b, 1c, 1e, 1f, 1g, 1i and 1j) the next step was to
examine their toxicity against the Vero cell line, at a concen-
tration 10 times their actual MIC value. A compound is
considered toxic if it causes over 50% inhibition of normal cells
at a concentration 10 fold higher than its MIC.36 From the
results (Table 6), it is clear that the tested compounds exhibited
moderate to low levels of cytotoxicity with a percentage survival
of the Vero cells in the range of 61 to 94%, and none of the tested
compounds exhibited any signicant cytotoxic eﬀects on theRSC Adv., 2015, 5, 64566–64581 | 64573
Table 4 Crystal data, data collection and structure reﬁnement (1e)
Empirical formula C14H13NO2S2
Formula weight 291.37
Temperature 293 K
Wavelength 0.71073 A˚
Crystal system, space group Triclinic, P1
Unit cell dimensions a ¼ 7.8774(2) A˚
b ¼ 8.4986(3) A˚
c ¼ 11.2330(3) A˚
a ¼ 91.435(2), b ¼ 107.376(2), g ¼ 107.927(2)
Volume 677.16(3) A˚3
Z 2
Calculated density 1.429 mg m3
Crystal size 0.22  0.15  0.12 mm
Absorption coeﬃcient 0.391 mm1
F(000) 304
Crystal form Plate, colourless
Radiation source Fine-focus sealed tube
Radiation type Mo Ka
Radiation monochromator Graphite
Criterion for observed reection I > 2s(I)
Data collection
Diﬀractometer Bruker SMART CCD area-detector
Data collection method u–c scans
Absorption correction Multi-scan
Theta range for data collection 1.92 to 29.02
Limiting indices 10 # h # 10, 11 # k # 11, 15 # l # 15
Reections collected/unique 13 042/3587 [R(int) ¼ 0.0236]
Completeness to theta 99.4%
Max. and min. transmission Tmax ¼ 1.000, Tmin ¼ 0.790
Renement
Renement method Full-matrix least-squares on F2
Data/restraints/parameters 3587/0/172
Goodness-of-t on F2 1.04
Final R indices [I > 2s(I)] R1 ¼ 0.0419, wR2 ¼ 0.1165
R indices (all data) R1 ¼ 0.0526, wR2 ¼ 0.1247
Weighting scheme u ¼ 1/[s2(Fo2) + (0.0653P)2 + 0.1591P] where P ¼ (Fo2 + 2Fc2)/3
(D/s)max <0.001
Largest diﬀ. peak and hole 0.508 and 0.490e Ǻ3
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View Article OnlineVero cells, suggesting great potential for their in vivo use as anti-
tubercular agents. As for the activity against Vero cells, the
highest cytotoxicity was caused by having –CH3 (1e) and –OCH3
(1g) substituents at the C-7 position of the coumarin, with aFig. 7 ORTEP and packing diagrams for compound 1e. Displacement e
shown as spheres of arbitrary radius.
64574 | RSC Adv., 2015, 5, 64566–64581percentage survival of 64 and 61% respectively. A second level of
cytotoxicity was observed for the –CH3 (1a) and –OCH3 (1c)
substituents at the C-6 position, with a percentage survival of 76
and 72% respectively. Whereas, the halogen-substitutedllipsoids are drawn at the 50% probability level. Hydrogen atoms are
This journal is © The Royal Society of Chemistry 2015
Fig. 8 ORTEP and packing diagrams for compound 1h. Displacement ellipsoids are drawn at the 50% probability level. Hydrogen atoms are
shown as spheres of arbitrary radius.
Table 5 Crystal data, data collection details and structure reﬁnement for 1h
Empirical formula C15H15NO2S2
Formula weight 305.40
Temperature 296 K
Wavelength 0.71073 A˚
Crystal system, space group Monoclinic, P21/c
Unit cell dimensions a ¼ 7.2356(8) A˚
b ¼ 7.9426(10) A˚
c ¼ 25.027(3) A˚
a ¼ 90, b ¼ 96.742(8), g ¼ 90
Volume 1428.4(3) A˚3
Z 4
Calculated density 1.420 mg m3
Crystal size 0.24  0.20  0.12 mm
Absorption coeﬃcient 0.373 mm1
F(000) 640
Crystal form Plate, yellow
Radiation source Fine-focus sealed tube
Radiation type Mo Ka
Radiation monochromator Graphite
Criterion for observed reection I > 2s(I)
Data collection
Diﬀractometer Bruker SMART CCD area-detector
Data collection method u–c scans
Absorption correction Multi-scan
Theta range for data collection 1.64 to 22.29
Limiting indices 7 # h # 7, 8 # k # 8, 26 # l # 26
Reections collected/unique 6121/1743 [R(int) ¼ 0.0536]
Completeness to theta 95.2%
Max. and min. transmission Tmax ¼ 1.000, Tmin ¼ 0.770
Renement
Renement method Full-matrix least-squares on F2
Data/restraints/parameters 1743/0/181
Goodness-of-t on F2 1.071
Final R indices [I > 2s(I)] R1 ¼ 0.0710, wR2 ¼ 0.1526
R indices (all data) R1 ¼ 0.0954, wR2 ¼ 0.1644
Weighting scheme u ¼ 1/[s2(Fo2) + (0.039P)2 + 4.4284P] where P ¼ (Fo2 + 2Fc2)/3
(D/s)max <0.001
Largest diﬀ. peak and hole 0.309 and 0.357e Ǻ3
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 64566–64581 | 64575
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Table 6 In vitro anti-tubercular screening data of the compounds (1a–1j) against MtbH37Rv
Compound R
% inhibition at
a concentration of 6.25 mg ml1 MICa (mg ml1)
% survival of Vero cells at a concentration
of 10  MICb log Pc
1a 6-CH3 93 1.56 76% 3.16
1b 6-Cl 98 0.09 94% 3.38
1c 6-OCH3 92 3.12 72% 2.76
1d 5,6-Benzo 16 N.D N.D 3.89
1e 7-CH3 91 6.25 64% 3.16
1f 7-Cl 94 0.39 88% 3.38
1g 7-OCH3 92 6.25 61% 2.76
1h 5,7-diCH3 23 N.D N.D 3.53
1i 6-Br 96 0.19 91% 3.52
1j 7-Br 94 0.78 81% 3.52
Isoniazid — 100 0.02 98% 0.97
a Minimum inhibitory concentration against the H37Rv strain ofMtb (mg ml
1). b A compound is considered toxic if it causes over 50% inhibition of
normal cells at a concentration 10 fold higher than its MIC. c Calculated using http://www.molinspiration.com/; N.D – not determined.
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View Article Onlinecompounds (1b, 1f, 1i and 1j) exhibited the highest safety
proles with a percentage survival of the Vero cells in the range
of 81–94%, which suggest that these compounds can act as new
leads for the development of new anti-tubercular drugs. Fig. 9
gives a comparison of the % survival of the Vero cells at a
concentration of the compound which is 10 fold higher than its
actual MIC value (mg ml1).Preliminary SAR study
Even though the number of compounds tested here is limited, a
few key features regarding the structural requirements for the
coumarin–thiazoline hybrids (1a–1j) to exert their anti-
tubercular activity may be determined. As we have discussed
in the Introduction section, our initial strategy was to identify
the key sub-units required for activity such as the coumarin,
thiazoline and thioether linker. Additionally, the substituents,
like R ¼ –CH3 (electron donating), –OCH3 (electron releasing),
–Br and –Cl (halogen), were varied at the C-6 and C-7 positions
of the coumarin, since modication of these positions is more
favorable for activity and the best output results were obtained
with substituents at these particular sites.5c,37 A fused benzo
substituent at the 5,6 position of the coumarin (1d) was also
involved in the series, since benzo groups fused to coumarinsFig. 9 Comparison of the percentage survival of the Vero cells at a
concentration of the compound which is 10 times its actual MIC value
(mg ml1).
64576 | RSC Adv., 2015, 5, 64566–64581have been reported in photocleavage studies,38 and their elec-
tronic along with their photo-physical characteristics have
resulted in promising biological applications.39 Hence based on
the structural data the following assumptions about the struc-
ture–activity relationship (SAR) were outlined.
From the results, it is clear that the group of compounds
having halogen (–Cl & –Br) substituents (1b, 1f, 1i and 1j) have
shownmore signicant anti-tubercular activity withMICs in the
range 0.09–0.78 mg ml1. Among them the halogen (–Cl & –Br)
substituents at the C-6 position of the coumarin moiety (1b and
1i) greatly enhanced the activity of the compound, obtaining
MIC values of 0.09 and 0.19 mg ml1 respectively; in particular,
the –Cl substituent at the C-6 position was found to be the most
active in vitro with a MIC of 0.09 mg ml1. A slight change in the
position of the halogen from the C-6 to C-7 position decreases
the overall activity of the compound, obtaining MIC values of
0.39 and 0.78 mg ml1 for 1f and 1j respectively. A second line of
activity was shown by the –CH3 (1a) and –OCH3 (1b) substituents
at the C-6 position of the coumarin obtainingMIC values of 1.56
and 3.12 mg ml1 respectively, whereas those compounds with
–CH3 (1e) and –OCH3 (1g) at the C-7 position of the coumarin
exhibited moderate activity with a similar MIC value of 6.25 mg
ml1. Here the substituents at the C-6 position have shown
much better results than those at the C-7 position of the
coumarin moiety; while the 5,6-benzo (1d) and 5,7-diCH3 (1h)
substituents were found to be inactive against the MtbH37Rv
strain. From the above results it is evident that the halogen
substituents dominated the overall activity. The reason for this
increase in activity may be attributed to the high lipophilic
nature of the halogen and it being less water soluble, hence
penetration of the drug or drug lead into a cell wall of lipid
membrane is much more easy and thereby the bioavailability of
the compound is increased.40 However, the other substituents
(–CH3, –OCH3, 5,6-benzo & 5,7-CH3) have shown mixed activity
and no proper SAR could be explained for these substituents.
Although it is worth mentioning that the –CH3, –OCH3 and
halogen substituents (–Cl & –Br) at the C-6 position were found
to be more active than the same substituents at the C-7 position
of the coumarin ring. The results from the preliminaryThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinestructure–activity analysis have led to the determination of
some key structural requirements for the coumarin–thiazoline
hybrids to exert their anti-TB activity, which provides insight for
further structural modications.Fig. 10 CT-DNA cleavage study using agarose gel electrophoresis.
Lane M: standard DNA marker, Lane C: control DNA (untreated
sample), Lane 1a: DNA + 1a, Lane 1b: DNA + 1b, Lane 1c: DNA + 1c,
Lane 1d: DNA + 1d, Lane 1e: DNA + 1e, Lane 1f: DNA + 1f, Lane 1g:
DNA + 1g, Lane 1h: DNA + 1h, Lane 1i: DNA + 1i, Lane 1j: DNA + 1j.Electrophoresis analysis
The design and development of small- or medium-sized
potential therapeutic agents to target nucleic acid cleavage
can lead to the synthesis of novel therapeutic agents for infec-
tious diseases and can act as a tool for molecular biology.
Interaction of small molecules with specic sites along a DNA
strand as a reactive model for protein–nucleic acid bindings
provides a path toward rational drug design as well as a means
to develop sensitive chemical probes for DNA. The diﬀerent loci
present in DNA are involved in various regulatory processes
such as gene expression, gene transcription, mutagenesis,
carcinogenesis, etc.41 In particular, designing of the compound
based on its ability to cleave DNA is of great importance not only
from the primary biological point of view but also in terms of a
photodynamic therapeutic approach to develop potent drugs.42
Hence to understand the mode of action of the synthesized
compounds (1a–1j) and to identify new molecules that induce
apoptosis, i.e. programmed cell death, we carried out a CT-DNA
cleavage assay using an agarose gel electrophoresis method,
and the results are presented in Fig. 10. The cleavage potential
of the test compounds was assessed by comparing the bands
that appeared for the control and test compounds at 5 mM
concentration. The DNA alone without the test compound was
used as a control, which did not show any cleavage of DNA even
aer a long exposure time. From the photograph (Fig. 10) it is
clear that compounds 1b, 1d, 1f and 1i cleaved the DNA more
eﬃciently, as no traces of DNA were found suggesting that the
cleavage of DNA by the compounds may be attributed to the
denaturation of double-stranded DNA by cleavage of the
hydrogen bonds between the nitrogen bases and the phospho-
diester bonds between the pentose sugars at various sites. In
addition, cleavage of the DNA might have occurred frequently
leading to low molecular weight fragments and these small
fragments have migrated away from the gel during electro-
phoresis. The remaining compounds 1a, 1c, 1g, 1h and 1j were
found to be inactive for cleavage of DNA, whereas a little tailing
of the band can be observed in the sample treated with
compound 1e indicating shearing of the DNA. From a structural
point of view it is observed that the halogen substituents at the 6
and 7 position of the coumarin moiety (1b, 1f, 1i and 1j)
exhibited nearly similar MIC values with distinct antitubercular
activity in the range 0.09–0.78 mg ml1, whereas in the DNA
cleavage assay, except for the –Br substituent at the 7 position
(1j), all the remaining halogen substituent compounds (1b, 1f
and 1i) cleave the DNA more eﬃciently. This indicates that the
nuclease activity may be dependent on the position of the –Br
group. Also, if we compare the MIC values of all the halogen-
substituted compounds, the compound with a –Br substituent
at the 7 position (1j) exhibited the least activity with a MIC of
0.78 mg ml1. Hence, this slight decrease in activity of
compound 1j may be attributed to not cleaving the genomicThis journal is © The Royal Society of Chemistry 2015DNA of the MtbH37 strain or that the target site of compound 1j
may be any other cell organelles of the MtbH37 strain but not
DNA. It is also noted that compound 1d, which was inactive
against the MtbH37 strain, cleaved DNA more eﬃciently. This
indicated that the nuclease activity is dependent on the
substituent attached to the coumarin moiety. Furthermore, the
concentration of compound 1d used for the in vitro assay may
be insuﬃcient to reach the target site, since in the DNA cleavage
assay the genomic DNA is directly subjected to the tested
compound whereas the MIC study is related to the resistance of
the strain (MtbH37) to the tested compound due tomany factors.
However, the nature of the reactive intermediates involved in
the DNA cleavage by the compounds has not been clear.Materials and methods
Instrumentation
Melting points were determined using an open capillary
method on a Buchi apparatus and are uncorrected. IR spectra
were recorded on a Nicolet 5700 FT-IR instrument (Nicolet,
Madison, WI, USA) using KBr discs. 1H NMR spectra were
recorded on a Bruker 400 MHz spectrometer using CDCl3 as the
solvent and TMS as an internal standard. All chemical shis are
reported as d values (ppm). Mass spectra were recorded using a
Shimadzu GCMSQP2010S. The elemental analyses were carried
out using a Hereaus CHN rapid analyzer. The microwave irra-
diation syntheses were carried out using a CEM-Discover
Focused Microwave system. The purity of the compounds was
checked using TLC. The X-ray single-crystal structures of
compounds 1a, 1b, 1e and 1h were recorded using a Bruker
Smart CCD and rened using the SHELXL Soware Package.General procedure for the preparation of compounds 1a–1j
Conventional method. A mixture of 4,5-dihydrothiazole-2-
thiol (0.01 mol) and powdered anhydrous K2CO3 (0.03 mol)
with the substituted 4-bromomethyl coumarin (0.01 mol) in 5
ml absolute ethanol was stirred at room temperature for 10–14
h. The progress of the reaction was examined using thin layer
chromatography (TLC). Aer completion of the reaction, the
reactionmixture was quenched in crushed ice; the solid product
was ltered and washed with water. Lastly, the product was
recrystallized from chloroform.
Microwave method. A mixture of 4,5-dihydrothiazole-2-thiol
(0.01 mol) and powdered anhydrous K2CO3 (0.03 mol) with theRSC Adv., 2015, 5, 64566–64581 | 64577
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View Article Onlinesubstituted 4-bromomethyl coumarin (0.01 mol) was put into a
10 ml microwave pressure vial and irradiated in a microwave
oven (model: CEM-Discover Focused Microwave system) under
100 W power at 55 C for 5–9 min in 5 ml absolute ethanol. The
progress of the reaction was examined using thin layer chro-
matography (TLC). Aer completion of the reaction, the reac-
tionmixture was quenched in crushed ice; the solid product was
ltered and washed with water. Lastly the product was recrys-
tallized from chloroform.Characterization of the compounds
4-[(4,5-Dihydro-1,3-thiazol-2-ylthio)methyl]-6-methyl-2H-
chromen-2-one (1a). Colourless crystals; mp 165–167 C; IR
(KBr) (vmax/cm
1): 1713 (C]O of lactone), 1574 (C]N of thia-
zole) cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 2.42 (s, 3H,
CH3), 3.45 (t, 2H, CH2, J¼ 8 Hz), 4.23 (t, 2H, CH2, J¼ 8 Hz), 4.45
(s, 2H, CH2), 6.56 (s, 1H, CH), 7.24 (d, 1H, Ar-H, J¼ 8.4 Hz), 7.34
(dd, 1H, Ar-H, J¼ 8.6 Hz, 2 Hz), 7.40 (s, 1H, Ar-H); 13C NMR (100
MHz, CDCl3, d ppm): 21.03, 32.06, 36.10, 63.89, 115.95, 117.10,
117.91, 124.01, 132.96, 134.00, 149.99, 151.96, 160.73, 163.59;
GC-MS: 291[M]+; anal. calcd for C14H13NO2S2: C, 57.71; H, 4.50;
N, 4.81%. Found: C, 57.68; H, 4.54; N, 4.85%.
6-Chloro-4-[(4,5-dihydro-1,3-thiazol-2-ylthio)methyl]-2H-
chromen-2-one (1b). Yellow crystals; mp 181–183 C; IR (KBr)
(vmax/cm
1): 1716 (C]O of lactone), 1577 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.55 (t, 2H, CH2, J¼ 8
Hz), 4.33 (t, 2H, CH2, J ¼ 8 Hz), 4.55 (s, 2H, CH2), 6.96 (s, 1H,
CH), 7.31 (d, 1H, Ar-H, J¼ 8.4 Hz), 7.54 (d, 1H, Ar-H, J¼ 8.4 Hz),
7.66 (s, 1H, Ar-H); 13C NMR (100 MHz, CDCl3, d ppm): 31.95,
36.05, 64.11, 116.13, 117.43, 118.21, 123.96, 133.06, 133.92,
150.08, 152.53, 160.11, 162.94; GC-MS: 311[M]+, 313[M + 2]+;
anal. calcd for C13H10ClNO2S2: C, 50.08; H, 3.23; N, 4.49%.
Found: C, 50.05; H, 3.28; N, 4.54%.
4-((4,5-Dihydrothiazol-2-ylthio)methyl)-6-methoxy-2H-
chromen-2-one (1c). Colourless crystals; mp 163–165 C; IR
(KBr) (vmax/cm
1): 1713 (C]O of lactone), 1584 (C]N of thia-
zole) cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.37 (t, 2H, CH2,
J¼ 8 Hz), 3.73 (s, 3H, –OCH3), 4.15 (t, 2H, CH2, J¼ 8 Hz), 4.52 (s,
2H, CH2), 6.48 (s, 1H, CH), 7.14 (d, 1H, Ar-H, J ¼ 8.4 Hz), 7.28
(dd, 1H, Ar-H, J ¼ 8.4 Hz, 1.6 Hz), 7.41 (s, 1H, Ar-H); 13C NMR
(100 MHz, CDCl3, d ppm): 32.40, 37.70, 55.44, 62.15, 115.40,
117.51, 118.97, 124.00, 132.01, 133.75, 149.91, 152.06, 159.73,
162.97; GC-MS: 307[M]+; anal. calcd for C14H13NO3S2: C, 54.70;
H, 4.26; N, 4.56%. Found: C, 54.75; H, 4.30; N, 4.60%.
1-((4,5-Dihydrothiazol-2-ylthio)methyl)-3H-benzo[f]
chromen-3-one (1d). Brown solid; mp 190–192 C; IR (KBr)
(vmax/cm
1): 1707 (C]O of lactone), 1601 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.43 (t, 2H, CH2, J¼ 8
Hz), 4.22 (t, 2H, CH2, J ¼ 8 Hz), 4.49 (s, 2H, CH2), 6.61 (s, 1H,
CH), 7.53–7.66 (m, 4H), 7.82 (dd, 1H, J¼ 8.4 Hz, 1.6 Hz), 8.48 (d,
1H, J¼ 8.8 Hz); 13C NMR (100MHz, CDCl3, d ppm): 32.58, 36.10,
63.91, 113.55, 115.20, 119.76, 122.56, 123.21, 124.30, 127.22,
127.63, 128.80, 134.75, 151.01, 151.07, 160.60, 163.53; GC-MS:
327[M]+; anal. calcd for C17H13NO2S2: C, 62.36; H, 4.00; N,
4.28%. Found: C, 62.39; H, 4.04; N, 4.25%.64578 | RSC Adv., 2015, 5, 64566–645814-((4,5-Dihydrothiazol-2-ylthio)methyl)-7-methyl-2H-
chromen-2-one (1e). Colourless crystals; mp 167–169 C; IR
(KBr) (vmax/cm
1): 1713 (C]O of lactone), 1597 (C]N of thia-
zole) cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 2.38 (s, 3H,
CH3), 3.41 (t, 2H, CH2, J¼ 8 Hz), 4.19 (t, 2H, CH2, J¼ 8 Hz), 4.41
(s, 2H, CH2), 6.51 (s, 1H, –CH), 7.18 (d, 1H, J ¼ 8.4 Hz), 7.30 (dd,
1H, J¼ 8.4 Hz, 1.6 Hz), 7.37 (s, 1H); 13C NMR (100MHz, CDCl3, d
ppm): 21.01, 32.05, 36.11, 63.88, 115.90, 117.05, 117.90, 124.02,
132.95, 134.01, 150.02, 151.92, 160.67, 163.55; GC-MS: 291[M]+;
anal. calcd for C14H13NO2S2: C, 57.71; H, 4.50; N, 4.81%. Found:
C, 57.75; H, 4.54; N, 4.83%.
7-Chloro-4-((4,5-dihydrothiazol-2-ylthio)methyl)-2H-
chromen-2-one (1f). Yellow crystals; mp 183–185 C; IR (KBr)
(vmax/cm
1): 1711 (C]O of lactone), 1579 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.45 (t, 2H, CH2, J¼ 8
Hz), 4.22 (t, 2H, CH2, J ¼ 8 Hz), 4.41 (s, 2H, CH2), 6.58 (s, 1H),
7.27 (d, 1H, J ¼ 8.8 Hz), 7.46 (dd, 1H, J ¼ 8.6 Hz, 2 Hz), 7.64 (s,
1H); 13C NMR (100 MHz, CDCl3, d ppm): 31.89, 36.23, 63.76,
117.01, 118.73, 119.36, 124.05, 129.79, 132.01, 149.34, 152.25,
159.80, 163.44; GC-MS: 311[M]+, 313[M + 2]+; anal. calcd for
C13H10ClNO2S2: C, 50.08; H, 3.23; N, 4.49%. Found: C, 50.05; H,
3.27; N, 4.45%.
4-((4,5-Dihydrothiazol-2-ylthio)methyl)-7-methoxy-2H-
chromen-2-one (1g). Colourless crystals; mp 165–167 C; IR
(KBr) (vmax/cm
1): 1716 (C]O of lactone), 1589 (C]N of thia-
zole) cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.40 (t, 2H,
–CH2, J ¼ 8 Hz), 3.83 (s, 3H, –OCH3), 4.21 (t, 2H, CH2, J ¼ 8 Hz),
4.41 (s, 2H, CH2), 6.59 (s, 1H), 7.20 (d, 1H, Ar-H, J ¼ 8 Hz), 7.31
(s, 1H, J ¼ 8.4 Hz), 7.40 (s, 1H); 13C NMR (100 MHz, CDCl3, d
ppm): 32.75, 36.66, 56.75, 63.08, 116.18, 117.14, 118.81, 123.75,
134.01, 134.68, 148.74, 152.31, 161.03, 163.42; GC-MS: 307[M]+;
anal. calcd for C14H13NO3S2: C, 54.70; H, 4.26; N, 4.56%. Found:
C, 54.75; H, 4.24; N, 4.60%.
4-((4,5-Dihydrothiazol-2-ylthio)methyl)-5,7-dimethyl-2H-
chromen-2-one (1h). Yellow crystals; mp 182–184 C; IR (KBr)
(vmax/cm
1): 1709 (C]O of lactone), 1597 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 2.29 (s, 3H, CH3),
2.64 (s, 3H, CH3), 3.41 (t, 2H, CH2, J¼ 8 Hz), 4.16 (t, 2H, CH2, J¼
8 Hz), 4.42 (s, 2H, CH2), 6.46 (s, 1H), 6.82 (s, 1H), 6.98 (s, 1H);
13C NMR (100 MHz, CDCl3, d ppm): 21.14, 23.95, 35.99, 36.15,
63.86, 115.25, 116.51, 116.57, 130.17, 135.57, 142.19, 151.29,
155.73, 160.42, 163.78; GC-MS: 305[M]+; anal. calcd for
C15H15NO2S2: C, 58.99; H, 4.95; N, 4.59%. Found: C, 58.75; H,
4.89; N, 4.63%.
6-Bromo-4-((4,5-dihydrothiazol-2-ylthio)methyl)-2H-
chromen-2-one (1i). Yellow crystals; mp 175–177 C; IR (KBr)
(vmax/cm
1): 1715 (C]O of lactone), 1601 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.51 (t, 2H, CH2, J¼ 8
Hz), 4.14 (t, 2H, CH2, J ¼ 8 Hz), 4.56 (s, 2H, CH2), 6.61 (s, 1H),
7.34 (d, 1H, J ¼ 8 Hz), 7.41 (d, 1H, J ¼ 7.6 Hz),7.60 (s, 1H); 13C
NMR (100 MHz, CDCl3, d ppm): 32.11, 36.01, 64.13, 117.12,
117.46, 120.16, 127.15, 133.63, 137.26, 149.81, 153.75, 161.13,
163.78; GC-MS: 311[M]+, 313[M + 2]+; anal. calcd for C13H10-
BrNO2S2: C, 43.83; H, 2.83; N, 3.93%. Found: C, 43.89; H, 2.87;
N, 3.98%.This journal is © The Royal Society of Chemistry 2015
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chromen-2-one (1j). Yellow crystals; mp 179–181 C; IR (KBr)
(vmax/cm
1): 1718 (C]O of lactone), 1583 (C]N of thiazole)
cm1; 1H NMR (400 MHz, CDCl3, d ppm) d 3.43 (t, 2H, CH2, J¼ 8
Hz), 4.21 (t, 2H, CH2, J ¼ 8 Hz), 4.48 (s, 2H, CH2), 6.61 (s, 1H),
7.41 (d, 1H, J ¼ 8.4 Hz), 7.61 (dd, 1H, J ¼ 7.6 Hz, 1.6 Hz), 7.82 (s,
1H); 13C NMR (100 MHz, CDCl3, d ppm): 33.09, 36.13, 64.22,
116.22, 117.49, 119.13, 126.82, 131.18, 135.12, 150.09, 153.49,
161.46, 164.03; GC-MS: 311[M]+, 313[M + 2]+; anal. calcd for
C13H10BrNO2S2: C, 43.83; H, 2.83; N, 3.93%. Found: C, 43.80; H,
2.89; N, 3.97%.
Anti-tubercular assay
All the compounds were rst screened at a concentration of 6.25
mg ml1 against M. tuberculosis H37Rv (ATCC-27294) in BACTEC
12 B medium using the Microplate Alamar Blue Assay (MABA).
Compounds exhibiting <90% inhibition in the primary
screening were not evaluated further, while compounds exhib-
iting >90% inhibition were re-tested against MtbH37Rv at lower
concentrations in order to determine the actual minimum
inhibitory concentration (MIC) in the MABA. The experiments
were carried out in triplicate using a 96-well plate; to each well
100 ml of Middlebrook 7H9 broth was added and a serial dilu-
tion of the compound was made directly on the plate. Firstly,
200 ml of sterile deionized water was added to all outer
perimeter wells of a sterile 96-well plate to minimize evapora-
tion of the medium in the test wells during incubation. Isoni-
azid was included as a positive drug control. The test
compounds were serially diluted using a two-fold serial dilution
method. The plates were covered and sealed with para lm and
incubated at 37 C for 5 days. Aer this, 25 ml of a freshly
prepared 1 : 1 mixture of Alamar Blue reagent and 10% tween
80 was added to the plate and incubated for 24 h. A blue color in
the wells indicated inhibition of bacterial growth while a pink
color was recorded as growth. Furthermore, the minimum
concentration of the compound required to inhibit the bacterial
growth was determined.
Assay for in vitro cytotoxicity against Vero cells
The cytotoxicity of the compounds with a MIC # 6.25 mg ml1
was evaluated using Vero cells. The Vero cells were cultured in
Dulbecco Modied Eagle Medium (DMEM) containing 2 mM
Na2CO3 supplemented with 10% (v/v) fetal bovine serum (FBS).
The cells were incubated at 37 C under 5% CO2 and 95% air in
a humidied atmosphere until conuent and then diluted with
phosphate-buﬀered saline to obtain 106 cells per ml. Stock
solutions were prepared in dimethyl sulfoxide (DMSO) and
further dilutions were made with fresh culture medium. The
medium was removed and replaced by 180 ml of fresh medium
containing the test compound at a concentration 10 fold its
actual MIC value. Aer incubation at 37 C for 72 h, the medium
was removed and the monolayer was washed twice with 100 mL
of warm Hanks’ balanced salt solution (HBSS). One hundred
microliters of warm medium and 20 mL of freshly made MTS-
PMS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium and phenylmethasulfazone]This journal is © The Royal Society of Chemistry 2015(100 : 20) (Promega) were added to each well, the plates were
incubated for 3 h, and the absorbance was determined at 560
nm using a microplate reader. The percentage of cell survival
was calculated aer considering the control wells (cells incu-
bated in DMSO-containing medium).
Sample preparation
Calf-Thymus DNA (CT-DNA) was procured from Merck Banga-
lore. A DNA stock solution was prepared by diluting the CT-DNA
in TE buﬀer. The test compounds (5 mM) were dissolved in
DMSO and added separately to the 10 ml of CT-DNA and then
incubated at 37 C for 2 h.
Agarose gel electrophoresis
The cleavage of Calf-Thymus DNA (CT-DNA) by the products was
analyzed using an agarose gel electrophoresis method. The gel
was prepared by adding 200 mg of agarose in 25 ml of TAE
buﬀer (4.84 g Tris base, pH 8.0, 0.5 M EDTA per 1 liter). The
mixture was heated to dissolve the agarose completely; there-
aer it was slightly cooled and 5 ml of ethidium bromide was
added. Then the molten agarose was poured into a casting tray
and a comb was placed in it for the formation of wells and it was
allowed to solidify. Aer solidication the comb was removed
and the tray was placed in a tank wherein the tank buﬀer (TAE)
was poured. Then the wells were loaded with 10 ml of DNA, 5 mm
of the test compound and 10 ml of the tracking dye (10 mM tris
pH 8.0, 1 mM EDTA, 30% glycerol, 0.2% bromophenol blue).
Electrophoresis was performed at 50 volts for 45 min. The gel
was visualized on a UV transilluminator for analysis of the
cleavage of the treated DNA sample by using untreated DNA as a
control and a marker was used to examine the molecular
weight. All the experiments were carried out in triplicate under
the same conditions.
Conclusion
The present study describes the synthesis of 4-[(4,5-dihydro-1,3-
thiazol-2-ylthio)methyl]substituted-2H-chromen-2-one deriva-
tives (1a–1j) under microwave irradiation which gives excellent
yields in a shorter reaction time as compared to the conven-
tional method. The most noticeable advancement in the
present study is the speed at which the reaction was completed
i.e. 5–9 minutes, which was 90–120 times faster than the
conventional method. Single X-ray crystals of compounds 1a,
1b, 1e and 1h were developed and their crystal parameters were
evaluated, which can contribute to the understanding of the
reactivity, aﬃnity and binding properties of the molecules. Anti-
tubercular activity screening revealed that compound 6-chloro-
4-[(4,5-dihydro-1,3-thiazol-2-ylthio)methyl]-2H-chromen-2-one
(1b) was found to be the most active in vitro, with a MIC of 0.09
mg ml1, and it exhibited a low level of cytotoxicity against Vero
cells, which suggests that compound 1b can act as promising
lead for the development of new anti-tubercular agents.
Furthermore, compounds 1b and 1i which were found to be the
most active in vitro against the MtbH37 strain were found to
cleave DNA completely, which further conrmed thatRSC Adv., 2015, 5, 64566–64581 | 64579
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agents. The obtained results suggest that the potent
compounds may serve as lead chemical entities for further
modication in the search for new classes of potential anti-
tubercular drugs.
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